CD19 and B-cell chronic lymphocytic leukemia: Groups from the MSKCC (Davila et al), the University of Pennsylvania (Grupp et al, Kalos et al, and Porter et al, all from Carl June’s group), the NCI (Dr Lee and Dr Kochenferder from Steve Rosenberg’s laboratory) presented data from pilot or phase I trials with anti-CD19 CAR-engineered T cells in paediatric and adult relapsed/refractory B cell malignancies (CLL, ALL, and non-Hodgkin lymphomas, and in one case a CD19-expressing T cell leukaemia).